Anne Altmeyer Biography and Net Worth

Director of Corbus Pharmaceuticals

Dr. Altmeyer is currently the President and CEO of TigaTx, Inc. She previously served as the Chief Business Officer of Sigilon Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of increasing responsibility in corporate development and program management over 15 years across large pharmaceutical organizations. Specifically, Dr. Altmeyer served as Vice President in Global Business Development at Baxalta and Vice President in Oncology Business Development and Companion Diagnostics at Novartis. Dr. Altmeyer began her industry career in program management roles at Merck & Company. She received her PhD from the University Louis Pasteur, Strasbourg, France, and did her postdoctoral fellowships at New York University and Cornell University Medical College in New York City. She also has an MBA from Rutgers University and a Masters in Public Health from the Robert Wood Johnson Medical School, in New Jersey.

What is Anne Altmeyer's net worth?: The estimated net worth of Anne Altmeyer is at least $70.15 thousand as of June 10th, 2026. Dr. Altmeyer owns 7,579 shares of Corbus Pharmaceuticals stock worth more than $70,151 as of July 24th. This net worth evaluation does not reflect any other investments that Dr. Altmeyer may own. Learn More about Anne Altmeyer's net worth.
How do I contact Anne Altmeyer?: The corporate mailing address for Dr. Altmeyer and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Anne Altmeyer's contact information.
Has Anne Altmeyer been buying or selling shares of Corbus Pharmaceuticals?: Anne Altmeyer has not been actively trading shares of Corbus Pharmaceuticals during the last ninety days. Most recently, Anne Altmeyer sold 2,412 shares of the business's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $7.91, for a transaction totalling $19,078.92. Following the completion of the sale, the director now directly owns 7,579 shares of the company's stock, valued at $59,949.89. Learn More on Anne Altmeyer's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), and Yuval Cohen (CEO). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $101,205.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 86,641 shares worth more than $1,177,188.36. The most recent insider tranaction occured on June, 10th when Director Winston Kung sold 2,026 shares worth more than $16,025.66. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 6/10/2026.

Anne Altmeyer Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2026	Sell	2,412	$7.91	$19,078.92	7,579
10/20/2025	Sell	1,060	$20.50	$21,730.00	6,191
5/30/2025	Sell	1,392	$7.25	$10,092.00	1,391

Anne Altmeyer Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $9.22

$8.93

$9.36

50 Day Range

MA: $8.79

$7.38

$11.51

2 Week Range

Now: $9.22

$7.12

$20.56

Volume

115,873 shs

Average Volume

332,724 shs

Market Capitalization

$170.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.55